From 11:00 pm to 12:00 pm EST ( 8:00 pm to 9:00 pm PST ) on January 6th, the website will be under maintenance. We are sorry for the inconvenience. Please arrange your schedule properly.
Carbonicanhydraseinhibitor 1 (compound 7c) is a carbonicanhydrase IIinhibitor. Carbonicanhydraseinhibitor 3 reduces the intraocular pressure in glaucomatous rabbits .
Carbonicanhydraseinhibitor 24 (Compound 11) is a human carbonicanhydrase(carbonicanhydrase)inhibitor. Ki values of Carbonicanhydraseinhibitor 24 for hCAs IX and XII were 10.7 and 7.5 nM, respectively .
Carbonicanhydraseinhibitor 3 (compound 11g) is a carbonicanhydrase IIinhibitor. Carbonicanhydraseinhibitor 3 reduces the intraocular pressure in glaucomatous rabbits .
Carbonicanhydraseinhibitor 12 is a potent CA IIinhibitor, also has inhibitory activity in CA I (Kis of 1.72 and 271 nM in CA II and CA I, respectively). Carbonicanhydraseinhibitor 12 has potent anticancer activity against different cancer cell lines .
Carbonicanhydraseinhibitor 4 is carbonicanhydrase photoprobe/inhibitor. Carbonicanhydraseinhibitor 4 is against human carbonicanhydrases (hCA I-XIV) with Ki values of 640-1166 nM .
Carbonicanhydraseinhibitor 15 (Compound 8) is a carbonicanhydraseinhibitor (Ki: 8.5 nM for hCA II). Carbonicanhydraseinhibitor 15 has analgesic effect .
Carbonicanhydraseinhibitor 25 (compound 6a) is a potent carbonicanhydraseinhibitor. Carbonicanhydraseinhibitor 25 shows inhibition for hCA I and hCA II receptor .
Carbonicanhydraseinhibitor 20 (compound 11) is an inhibitor of piperazinosulfonamide carbonicanhydrase(CarbonicAnhydrase). The Ki of Carbonicanhydraseinhibitor 20 for hCA I, hCA II, hCA IX, and hCA XII are 47.6 nM, 36.5 nM, 8.3 nM, and 2.7 nM respectively .
Carbonicanhydraseinhibitor 28 (Compound 11) is a Pseudomonas aeruginosacarbonicanhydraseinhibitor. Carbonicanhydraseinhibitor 28 exhibits antimicrobial activity, with a MIC of 0.5 μg/mL and a MBC of 1 μg/mL against P. aeruginosa. Carbonicanhydraseinhibitor 28 can be used in anti-infection research .
Carbonicanhydraseinhibitor 11 (compound VI) is a potent, selective carbonicanhydraseinhibitor. Carbonicanhydraseinhibitor 11 shows Ki values of 40, 39, 200 and 900 nM against CA II, IX, and XII, respectively .
Carbonicanhydraseinhibitor 21 (Compound 5h) is a selective carbonicanhydrase (hCA IX)inhibitor, with a Ki of 15.1 nM, and is highly selective against other investigated isoform. Carbonicanhydraseinhibitor 21 can be used for anticancer research .
Carbonicanhydraseinhibitor 14 (Compound 8b) is a carbonicanhydrase (CA)inhibitor with Ki values of 1203, 99.7, 9.4 and 27.7 nM against hCA I, hCA II, hCA IX and hCA XII, respectively. Carbonicanhydraseinhibitor 14 can also inhibitCDK2 with an IC50 of 20.3 μM. Carbonicanhydraseinhibitor 14 shows antitumor activity .
Carbonicanhydraseinhibitor 10 is a potent hCA IXinhibitor with a Ki value of 6.2 nM. Carbonicanhydraseinhibitor 10 exhibits anti-proliferative activity against MCF-7 cancer cell line with an IC50 of 11.9 μM. Carbonicanhydraseinhibitor 10 can be used for cancer research .
Carbonicanhydraseinhibitor 9 is a potent carbonicanhydrase (CA)inhibitor with Kis of 56.4 and 56.9 nM for hCA II and IX, respectively. Antiproliferative activity .
Carbonicanhydraseinhibitor 18 (Compound 9) is a human carbonicanhydrase (hCA) isoform inhibitor, with Kis of 604.8, 333.6, 1.9 and 6.7 nM for hCA I, hCA II, hCA IX and hCA XII, respectively. Carbonicanhydraseinhibitor 18 can be used for the research of cancer .
Carbonicanhydraseinhibitor 16 (compound 1) is a dengue protease inhibitor with inhibitory activity against carbonicanhydrasehCA I and hCA II (Ki: 28.5 nM, 2.2 nM) .
Carbonicanhydraseinhibitor 23 (compound 40) is a potent inhibitor of carbonicanhydrase (CA), with the Ki of 617.2 nM and 434.1 nM for hCA I (α) and hCA II (α), respectively .
Carbonicanhydraseinhibitor 5 is a potent and selective human carbonicanhydrase (hCA)inhibitor with IC50s of 42.9, 47,6 and 6.7 nM for hCA II, hCA IX and hCA XII, respectively .
Carbonicanhydraseinhibitor 19 (compound 26a) inhibits the Glaucoma related isoforms hCA II and hCA XII with Kis of 9.4 nM and 6.7 nM, respectively. Carbonicanhydraseinhibitor 19 reveals an intraocular pressure (IOP) lowering effect .
Carbonicanhydraseinhibitor 13 (compound 7) is a potent carbonicanhydrase (CA)inhibitor, which features 3-methylthiazolo[3,2-a]benzimidazole moiety (as a tail) connected to the zinc anchoring benzenesulfonamide moiety via ureido linker .
Carbonicanhydraseinhibitor 7 (compound 5b) is a potent inhibitor of human carbonicanhydrase (hCA), with Kis of 6.5 nM, 7.1 nM, 72.1 nM, and 255.8 nM for hCA IX, hCA II, hCA XII and hCA I, respectively .
Carbonicanhydraseinhibitor 6 (compound 9b) is a potent inhibitor of human carbonicanhydrase (hCA), with Kis of 9.7 nM, 35.2 nM, 88.5 nM, and 91.8 nM for hCA IX, hCA II, hCA XII and hCA I, respectively .
Carbonicanhydraseinhibitor 27 (compund 5g) is an antitrypanosomal agent that reduces parasites in the bloodstream and improves survival of infected mice .
Antibacterial agent 167 (compound 13) is an inhibitor of pathogenic bacterial carbonicanhydrases. Antibacterial agent 167 inhibits the growth of N. gonorrhea strains at concentrations ranging from 16 to 64 µg/mL .
Sezolamide hydrochloride (MK 417) is a potent topical carbonicanhydraseinhibitor. Sezolamide hydrochloride can be used in studies to reduce intraocular pressure .
Dichlorphenamide (Diclofenamide) disodium is an orally active, specific, carbonicanhydraseinhibitor. Dichlorphenamide can reduce intraocular pressure by inhibiting the secretion of water from the eye. Dichlorphenamide can be used for glaucoma research .
hBChE-IN-3 (compound 30) is a combination of carbonicanhydrase (CA) activator and cholinesterase (ChE) inhibitor with IC50 values of 7.4 and 1.9 nM for AchE and BchE, respectively. hBChE-IN-3 can be used in the study of neurodegeneration and psychiatric disorders .
Lasamide (Standard) is the analytical standard of Lasamide. This product is intended for research and analytical applications. Lasamide is a potent human CarbonicAnhydraseinhibitor with Ki values of 7.54 and 2.76 nM for hCAXII and hCAIX, respectively .
FC14-584B, a dithiocarbamate, is a β-CarbonicAnhydraseinhibitor. FC14-584B inhibits the growth of trophozoites. FC14-584B can be used for the research of tuberculosis .
hCAII-IN-6 (Compound S-13) is a potent human carbonicanhydrase II (hCA II)inhibitor with a Ki of 4.4 nM. hCAII-IN-6 also inhibits other hCAs isoforms I, IV and IX, with Ki values of 9.2 nM, 480.2 nM and 14.7 nM, respectively. hCAII-IN-6 can be used for glaucoma research .
CDK2-IN-12 (compound 10b) is a potent CDK2inhibitor, with an IC50 of 11.6 μM. CDK2-IN-12 inhibitshCA (carbonicanhydrase) isoforms I, II, IX and XII, with KI values of 3534, 638.4, 44.3, and 48.8 nM. CDK2-IN-12 shows anticancer activity .
Disulfamide, an orally active diuretic, is a carbonicanhydraseinhibitor with the IC50 value of 0.07 μM. Disulfamide leads to diuresis by inhibitingcarbonicanhydrase and preventing the reabsorption of sodium and bicarbonate in the proximal tubule .
Carbonicanhydrase/AChE-IN-1 (compound 16) is a carbonicanhydrase and AChEinhibitor with Kis of 24.42 nM, 19.95 nM, and 5.07 nM for hCA I, hCA II, and AChE, respectively .
Enpp/Carbonicanhydrase-IN-2 (compound 1i) is a potent Enpp and carbonicanhydraseinhibitor with IC50s of 1.13, 1.07, 0.74, 0.33, 0.68 for NPP1, NPP2, NPP3, CA-IX, CA-XII respectively. Enpp/Carbonicanhydrase-IN-2 shows antiproliferative activity for cancer cells and low cytotoxic against normal cells. Enpp/Carbonicanhydrase-IN-2 induces Apoptosis .
Enpp/Carbonicanhydrase-IN-1 (compound 1e) is a potent Enpp and carbonicanhydraseinhibitor with IC50s of 1.36, 1.35, 3.00, 0.88, 1.02 μM for NPP1, NPP2, NPP3, CA-II, CA-IX respectively. Enpp/Carbonicanhydrase-IN-1 shows antiproliferative activity for cancer cells and low cytotoxic against normal cells. Enpp/Carbonicanhydrase-IN-1 induces Apoptosis .
Carbonicanhydrase/AChE-IN-2 (compound 19) is a selective acetylcholinesterase (AChE) and carbonicanhydrase (CA) inhibitor, with Ei of 5.07 nM, 24.42 nM and 19.95 nM for AChE, hCAI and hCAII, respectively .
ALP/Carbonicanhydrase-IN-1 (Compound 1e) is a dual carbonicanhydrase (CA) and alkaline phosphatase (ALP)inhibitor. ALP/Carbonicanhydrase-IN-1 shows IC50 values of 0.44 µM, 1.61 µM, 0.51 µM, and 0.107 µM for CA-II, CA-IX, CA-XII, and ALP, respectively .
CAII-IN-2 (compound 3g), a thiosemicarbazide derivative, is a potent, selective carbonicanhydrase-II (CA-II)inhibitor with an IC50 value of 12.1 µM for bovine CA-II. CAII-IN-2 can be used in research of carbonicanhydrase related biological disorders .
CAII-IN-1 (compound 3n), a thiosemicarbazide derivative, is a potent, selective carbonicanhydrase-II (CA-II)inhibitor with an IC50 value of 10.3 µM for bovine CA-II. CAII-IN-1 can be used in research of carbonicanhydrase related biological disorders .
hCAI/II-IN-9 is a carbonicanhydraseinhibitor with inhibitory activity against human carbonicanhydrase isoforms I, II, IX, and XII. The inhibition constants (Ki) of hCAI/II-IN-9 for hCA I are in the range of 7.9-894 nM, for hCA II are in the range of 7.5-1645 nM, for hCA IX are in the range of 5.0-240 nM, and for hCA XII are in the range of 0.47-2.83 nM. hCAI/II-IN-9 may have potential applications in inhibiting a variety of pathologies involving these carbonicanhydrase isoforms .
Methazolamide-d6 is the deuterium labeled Methazolamide. Methazolamide (L584601) is a sulfonamide derivative used as a carbonicanhydraseinhibitor with a Ki of 14 nM for human carbonicanhydrase II. Methazolamide, an intraocular pressure-lowering agent, reduces intraocular pressure elevations associated with glaucoma and other ocular disorders[1][2].
Methazolamide (L584601) is a BBB-penatrable and orally active carbonicanhydraseinhibitor, with a Ki of 14 nM for human carbonicanhydrase II. Methazolamide can reduce intraocular pressure and has a neuroprotective effect, being able to inhibit neuronal apoptosis. Methazolamide can be used in the research of ophthalmic diseases such as glaucoma and cerebrovascular diseases such as subarachnoid hemorrhage .
hCA I-IN-3 (compound 24), an aryl ether derivative, is a potent carbonicanhydraseinhibitor. hCA I-IN-3 can inhibitcarbonicanhydrasehCA I and hCA II isoenzymes, with IC50 values of 4.77 and 9.66 nM, respectively. hCA I-IN-3 can be used for cancer research .
Quinethazone is an orally active diuretic agent and is also a weak inhibitor of carbonicanhydrase. Quinethazone can be used for hypertension research .
Sultiame (Standard) is the analytical standard of Sultiame. This product is intended for research and analytical applications. Sultiame is a carbonicanhydraseinhibitor, widely used as an antiepileptic agent.
Methazolamide (Standard) is the analytical standard of Methazolamide. This product is intended for research and analytical applications. Methazolamide (L584601) is a BBB-penatrable and orally active carbonicanhydraseinhibitor, with a Ki of 14 nM for human carbonicanhydrase II. Methazolamide can reduce intraocular pressure and has a neuroprotective effect, being able to inhibit neuronal apoptosis. Methazolamide can be used in the research of ophthalmic diseases such as glaucoma and cerebrovascular diseases such as subarachnoid hemorrhage .
Tioxolone (Standard) is the analytical standard of Tioxolone. This product is intended for research and analytical applications. Tioxolone is an inhibitor of the metalloenzyme carbonicanhydrase I and has anti-acne activity.
Acetazolamide sodium is a carbonicanhydrase (CA) IXinhibitor with an IC50 of 30 nM for hCA IX. Acetazolamide sodium has diuretic, antihypertensive and anti-gonococcal activities .
O-Desmethyl Brinzolamide hydrochloride (compound 6a), an active metabolite of Brinzolamide, is a carbonicanhydrase (CA)inhibitor with a Kd of 0.136 nM for CA II and an IC50 of 165 nM for CA IV .
Acetazolamide is a carbonicanhydrase (CA) IXinhibitor with an IC50 of 30 nM for hCA IX. Acetazolamide has diuretic, antihypertensive and anti-gonococcal activities .
Dichlorphenamide (Diclofenamide) is an orally active, specific, carbonicanhydraseinhibitor. Dichlorphenamide can reduce intraocular pressure by inhibiting the secretion of water from the eye. Dichlorphenamide can be used for glaucoma research .
Chloraminophenamide (Compound 14) is a carbonicanhydraseinhibitor, with Kis of 75, 160 and 8400 nM for hCA II, bCA IV and hCA I, respectively. Chloraminophenamide has the potential for antiglaucoma research .
AChE/hCA I-IN-1 (Compound L3) is the inhibitor for acetylcholinesterase (AChE) and carbonicanhydrase (CA), that inhibitsAChE, hCA I and hCA II with IC50 of 302, 265 and 283 nM, respectively .
AHR-15010 is an oral active carbonicanhydraseinhibitor with the IC50 of 0.13 μM. AHR-15010 shows anti-arthritic activity and can be used for study of arthritis .
Benzenesulphonamide (Standard) is the analytical standard of Benzenesulphonamide. This product is intended for research and analytical applications. Benzenesulphonamide (compound 1) is a potent carbonicanhydraseinhibitor. Benzenesulphonamide shows CA II inhibitory activity .
Benzenesulphonamide (Standard) is the analytical standard of Benzenesulphonamide. This product is intended for research and analytical applications. Benzenesulphonamide (compound 1) is a potent carbonicanhydraseinhibitor. Benzenesulphonamide shows CA II inhibitory activity .
Lasamide (Standard) is the analytical standard of Lasamide. This product is intended for research and analytical applications. Lasamide is a potent human CarbonicAnhydraseinhibitor with Ki values of 7.54 and 2.76 nM for hCAXII and hCAIX, respectively .
Halazone is an atypical antimicrobial sulfonamide derivative and a carbonicanhydrase IIinhibitor with a Kd value of 1.45 µM. Halazone protects sodium channels from inactivation. Halazone is widely used for disinfection of drinking water .
hCAI/II-IN-7 (compound 1F) is a potent carbonicanhydrase (CA)inhibitor with Ki values of 23 nM, 44 nM and 20.57 µM for hCA-I, hCA-II and bovine CA, respectively .
hCAI/II-IN-2 (compound 2b) is a potent dual hCA I/II inhibitor with Ki values of 40.97, 15.15 and 61.88 nM for hCA I, hCA II and hCA Ⅸ. hCAI/II-IN-2 possesses anti-hypoxic activity against acute mountain sickness (AMS) and low cellular activity .
hCAI/II-IN-3 (compound 5b) is a potent dual hCA I/II inhibitor with Ki values of 51.25, 13.15 and 42.18 nM for hCA I, hCA II and hCA Ⅸ. hCAI/II-IN-3 possesses anti-hypoxic activity against acute mountain sickness (AMS) and low cellular activity .
Dorzolamide (L671152) is a potent carbonicanhydrase II inhibitor, with IC50 values of 0.18 nM and 600 nM for red blood cell CA-II and CA-I respectively. Dorzolamide possesses anti-tumor activity .
ulfanilamide (Sulphanilamide) is a potent and orally active sulfonamide antibiotic and can be a major intermediate of sulfamethoxazole biodegradation. Sulfanilamide also is a carbonicanhydraseinhibitor. Sulfanilamide shows inhibition on virus of lymphogranuloma venereum .
Dorzolamide (L671152) hydrochloride is a potent carbonicanhydrase II inhibitor, with IC50 values of 0.18 nM and 600 nM for red blood cell CA-II and CA-I respectively. Dorzolamide possesses anti-tumor activity .
Procodazole is an orally active enhancer and a non-specific active immune protector against viral and bacterial infections. Procodazole also exhibits antiparasitic activity. In addition, Procodazole is a carbonicanhydraseinhibitor with antitumor activity .
Indan-5-sulphonamide (Compd 1) is a carbonicanhydraseinhibitor and anticonvulsant agent, with Ki values of 0.039 nM (hCA XII), 6.5 nM (hCA XIV) and 5.1 nM (hCA XIV), respectively .
hCAIX-IN-20 (compound APBS-5m) is a potent inhibitor of carbonicanhydrase IX (hCA IX), with the Ki of 2.7 nM. hCAIX-IN-20 plays an important role in cancer research .
hCAII-IN-7 (Compound R-13) is a potent human carbonicanhydrase(hCA)inhibitor with Kis of 60.7, 320.7, 2298, and 35.2 nM for hCA I, II, IV and IX, respectively .
hCAII-IN-3 (compound 7e) is a potent and selective inhibitor of carbonicanhydrase (CA II/IX) with Kis of 124.2 and 30.5 nM, respectively. hCAII-IN-3 has the potential for the research of cancer diseases .
DTA (Standard) is the analytical standard of DTA. This product is intended for research and analytical applications. DTA (2,4-Disulfamyl-5-trifluoromethylaniline) is a cyclic AMP phosphodiesterase inhibitor that binds to erythrocyte carbonicanhydrase .
hCAII-IN-1 (compound 7f) is a potent and selective inhibitor of carbonicanhydrase (CA II/IX) with Kis of 1.2 and 113.6 nM, respectively. hCAII-IN-1 has the potential for the research of cancer diseases .
DTA (Standard) is the analytical standard of DTA. This product is intended for research and analytical applications. DTA (2,4-Disulfamyl-5-trifluoromethylaniline) is a cyclic AMP phosphodiesterase inhibitor that binds to erythrocyte carbonicanhydrase .
hCAIX/XII-IN-9 (compound 8) is a potent carbonicanhydrase (CA)inhibitor with Ki values of 1658 nM, 184.8 nM, 8.9 nM, 64.8 nM for hCA I, hCA II, hCA IX, and hCA XII, respectively .
Anti-inflammatory agent 67 (compound 7a) is a dual inhibitor of carbonicanhydrase and COX-2, a sulfonamide derivative of Polmacoxib (HY-16726), and has anti-inflammatory properties and analgesic activity. Anti-inflammatory agent 67 has IC50s of 10.4 μM and 50 nM for COX-1 and COX-2, respectively. The Ki of anti-inflammatory agent 67 binding to different isoforms of carbonicanhydrase are 48.3 nM (CA I), 42.2 nM (CA II), 52.3 nM (CA IX), and 13.3 nM (CA XII) .
Anti-inflammatory agent 68 (compound 7b) is a dual inhibitor of carbonicanhydrase and COX-2, a sulfonamide derivative of Polmacoxib (HY-16726), with anti-inflammatory properties and analgesic activity. Anti-inflammatory agent 68 has IC50s of 12.6 μM and 60 nM for COX-1 and COX-2, respectively. The Ki of anti-inflammatory agent 68 binding to different isoforms of carbonicanhydrase are 52.6 nM (CA I), 79.1 nM (CA II), 58.1 nM (CA IX), and 17.2 nM (CA XII) .
4-Acetylphenylboronic acid is a potent inhibitor of carbonicanhydrases II(CA II), with IC50s of 246 μM and 281.40 μM for bovine CA II (bCA II) and human CA II (hCA II), respectively .
SH7s is a potent carbonicanhydrasesinhibitor, with Kis of 15.9 and 55.2 nM for hCA IX and hCA XII, respectively. SH7s is also a hypoxia-mediated chemo-sensitizing agent in colorectal cancer cells .
4-Chloro-3-sulfamoylbenzoic acid is an inhibitor of human carbonicanhydrase, targeting the cytosolic isoforms hCA I and hCA II (glaucoma-associated), and the transmembrane isoforms hCA IV and hCA IX (tumor hypoxia-induced) .
hCAIX-IN-18 (compound 30) is an inhibitor of carbonicanhydrase (CA), with Kis of 3.5 nM, 9.4 nM, 43.0 nM and 8.2 nM for hCAI, hCAII, hCAIX, hCAXII, respectively. hCAIX-IN-18 can be used for cancer research .
hCAI/II-IN-1 (Compound 3h) is a human carbonicanhydrase I and II (hCA I/II) inhibitor with IC50 values of 0.047 µM and 0.024 µM against hCA I and hCA II, respectively .
Acetazolamide (Standard) is the analytical standard of Acetazolamide. This product is intended for research and analytical applications. Acetazolamide is a carbonicanhydrase (CA) IXinhibitor with an IC50 of 30 nM for hCA IX. Acetazolamide has diuretic, antihypertensive and anti-gonococcal activities .
Acetazolamide- 13C2,d3 is the 13C- and deuterium labeled Acetazolamide. Acetazolamide is a carbonicanhydrase (CA) IX inhibitor with an IC50 of 30 nM for hCA IX[1]. Diuretic effects[4].
Brinzolamide (AL-4862) hydrochloride is a selective carbonicanhydrase IIinhibitor with an IC50 value of 3.2 nM. Brinzolamide hydrochloride reduces intraocular pressure (IOP) by inhibiting ciliary CA-II and decreasing atrial fluid secretion. Brinzolamide hydrochloride can be used in glaucoma disease research .
Dichlorphenamide (Standard) is the analytical standard of Dichlorphenamide. This product is intended for research and analytical applications. Dichlorphenamide (Diclofenamide) is an orally active, specific, carbonicanhydraseinhibitor. Dichlorphenamide can reduce intraocular pressure by inhibiting the secretion of water from the eye. Dichlorphenamide can be used for glaucoma research .
hCA I-IN-2 (Compound 6d) is a selective human carbonicanhydrase I (hCA I)inhibitor with Ki values of 18.8, 375.1, 1721 and 283.9 nM against hCA I, hCA II, hCAIX and hCAXII, respectively .
hCA I-IN-1 (Compound 6q) is a human carbonicanhydrase I (hCA I)inhibitor with Ki values of 38.3, 716.4, 940.1 and 192.8 nM against hCA I, hCA II, hCAIX and hCAXII, respectively .
hCAII-IN-2 (Compound 11f) is a cytosolic human carbonicanhydrase (hCA)inhibitor with Ki values of 261.4, 3.8, 19.6 and 45.2 nM against hCA I, hCA II, hCA IX and hCA XII, respectively .
Polmacoxib (CG100649) is a first-in-class, orally active nonsteroidal anti-inflammatory agent (NSAID) which is a dual inhibitor of COX-2 (IC50 around 0.1 μg/ml) and carbonicanhydrase . Polmacoxib inhibits colorectal adenoma and tumor growth in mouse models .
Brinzolamide (AL-4862) is a selective carbonicanhydrase IIinhibitor with anIC50 value of 3.2 nM. Brinzolamide hydrochloride reduces intraocular pressure (IOP) by inhibiting ciliary CA-II and decreasing atrial fluid secretion. Brinzolamide can be used in glaucoma disease research .
L-645151 is a carbonicanhydraseinhibitor with ocular penetration and hypotensive activity. L-645151 lowers the elevated intraocular pressure (IOP) of o-chymotripsinized (o-CT) rabbit eyes. L-645151 is promising for research of an ocular hypotensive agent .
U-104 (SLC-0111) is a potent carbonicanhydrase (CA)inhibitor for CA IX and CA XII with Ki values of 45.1 nM and 4.5 nM, respectively. U-104 shows a significant delay in tumor growth in mice model .
Benzthiazide is a long-acting diuretic and a hypertension agent. Benzthiazide is an inhibitor of carbonicanhydrase 9 (CA9), with Kis of 8.0, 8.8 and 10 nM for CA9, CA2 and CA1, respectively. Benzthiazide also suppresses proliferation of cancer cells .
hCAIX/XII-IN-10 (compound DK-8) is a carbonicanhydraseinhibitor. hCAIX/XII-IN-10 has potent inhibitory activity against tumor-associated membrane-bound isoforms hCA IX and XII, with Ki values of 32.5 nM and 29.2 nM .
DTP348 is an inhibitor for carbonicanhydrase IX with a Ki of 8.3 nM in vitro and an IC50 of 19.26 μM in Xenopus oocytes. DTP348 exhibits slight toxicity in zebrafish embryos with LD50 of 3.5 mM. DTP348 can be used in the anti-cancer research .
hCAXII-IN-2 (compound 5i) is a potent human carbonicanhydrase XII (hCA XII) and hCA IXinhibitor with Ki values of 84.2 nM and 268.5 nM, respectively. hCAXII-IN-2 shows less active against hCA I and hCA II .
Benzolamide (CL11366) is a potent carbonicanhydrase (CA)inhibitor, with Kis of 15 nM, 9 nM, 94 nM and 78 nM for hCA I, hCA II, EcoCAγ and VchCAγ, respectively. Benzolamide also inhibitsCAS3, with a Ki of 54 nM. Benzolamide can be used for the research of glaucoma and seizures .
hCAII-IN-9 is a potent carbonicanhydrase inhibitor with IC50s of 1.18 μM (hCA II), 0.17 μM (hCA IX), and 2.99 μM (hCA XII), respectively. hCAII-IN-9 has no blood-brain barrier permeability .
hCAXII-IN-10 (Compound 18b) is a dual inhibitor of human carbonicanhydrase isoform XII (hCAXII) and cathepsin B, with a Ki value of 2.2 nM. hCAXII-IN-10 can inhibit the role of hCAXII in providing tumors with a pH microenvironment conducive to tumor growth, and is expected to be used in the study of tumor diseases .
Dorzolamide-d5 is the deuterium labeled Dorzolamide. Dorzolamide (L671152) is a potent carbonicanhydrase II inhibitor, with IC50 values of 0.18 nM and 600 nM for red blood cell CA-II and CA-I respectively. Dorzolamide possesses anti-tumor activity[1][2].
JNJ-26990990 is a broad-spectrum antiepileptic agent with oral activity. JNJ-26990990 can inhibit voltage-gated Na + channels and N-type Ca 2+ channels, but has a very weak inhibitory effect on human carbonicanhydrase-II (IC50 = 110 μM) .
Chlorzolamide (CL 13580) is a carbonicanhydrase (CA) inhibitor. Chlorzolamide has an effect on the skeletal muscle of rats, which can reduce the tetanic contraction force of soleus and extensor digitorum longus and prolong the relaxation time and peak time of muscle contraction. In addition, Chlorzolamide inhibits tumor cell proliferation and has antitumor activity .
hCA I-IN-4 (Compound 14) is the inhibitor for carbonicanhydrase and cholinesterase, that inhibitshCA I, hCA II, AChE, and BChE with Ki of 29.94 nM, 17.72 nM, 21.21 nM, and 7.65 nMrespectively. hCA I-IN-4 exhibits cytotoxicity in BT-549 with IC50 of 16.59 μM .
Furagin (Furazidine), an analogue of Nitrofurantoin (HY-A0090), is an antibiotic with antibacterial activity against ESKAPE pathogens with MIC values of 0-32 µg/mL. Furagin inhibits human Carbonicanhydrases . Furagin is promising for research of cancer and urinary tract infections (UTIs) .
hCAII-IN-3 (Compound 16) is a human carbonicanhydrase (hCA) inhibitor with Ki values of 403.8, 5.1, 10.2 and 5.2 nM against hCA I, hCA II, hCA IX and hCA XII, respectively. hCA IX-IN-2 shows anticancer activity .
Sulfanilamide (Standard) is the analytical standard of Sulfanilamide. This product is intended for research and analytical applications. ulfanilamide (Sulphanilamide) is a potent and orally active sulfonamide antibiotic and can be a major intermediate of sulfamethoxazole biodegradation. Sulfanilamide also is a carbonicanhydraseinhibitor. Sulfanilamide shows inhibition on virus of lymphogranuloma venereum .
Dorzolamide (hydrochloride) (Standard) is the analytical standard of Dorzolamide (hydrochloride). This product is intended for research and analytical applications. Dorzolamide (L671152) hydrochloride is a potent carbonicanhydrase II inhibitor, with IC50 values of 0.18 nM and 600 nM for red blood cell CA-II and CA-I respectively. Dorzolamide possesses anti-tumor activity .
Furagin (Standard) is the analytical standard of Furagin. This product is intended for research and analytical applications. Furagin (Furazidine) is an analogue of Nitrofurantoin (HY-A0090) and has antibacterial activity. Furagin also inhibits human carbonicanhydrases (Kis: 260 and 57 nM for hCA IX and XII, respectively) .
Dorzolamide-d3 hydrochloride is deuterated labeled Dorzolamide hydrochloride (HY-B0109A). Dorzolamide (L671152) hydrochloride is a potent carbonicanhydrase II inhibitor, with IC50 values of 0.18 nM and 600 nM for red blood cell CA-II and CA-I respectively. Dorzolamide possesses anti-tumor activity .
hCA IX-IN-1 (Compound 6f) is a human carbonicanhydrase (hCA) inhibitor with Ki values of 331.4, 28.4, 9.4 and 17.8 nM against hCA I, hCA II, hCA IX and hCA XII, respectively. hCA IX-IN-1 shows anticancer activity .
Fluorometholone acetate is a synthetic glucocorticoid corticosteroid and a corticosteroid ester. Fluorometholone acetate potently inhibitscarbonicanhydrase (CA) with IC50s of 2.18 μM and 17.5 μM for hCA-I and hCA-II, respectively. Fluorometholone acetate has anti-inflammatory effect and has the potential for external ocular inflammation research .
hCAIX/XII-IN-6 is an orally active carbonicanhydrase (CA)inhibitor. hCAIX/XII-IN-6 inhibits human CA isoforms hCA I, II, IV, IX, and XII with Ki values of 6697 nM, 2950 nM, 4093 nM, 4.1 nM and 7.7 nM, respectively. hCAIX/XII-IN-6 can be used for the research of rheumatoid arthritis (RA) .
Brinzolamide (Standard) is the analytical standard of Brinzolamide. This product is intended for research and analytical applications. Brinzolamide (AL-4862) is a selective carbonicanhydrase IIinhibitor with anIC50 value of 3.2 nM. Brinzolamide hydrochloride reduces intraocular pressure (IOP) by inhibiting ciliary CA-II and decreasing atrial fluid secretion. Brinzolamide can be used in glaucoma disease research .
Polmacoxib (Standard) is the analytical standard of Polmacoxib. This product is intended for research and analytical applications. Polmacoxib (CG100649) is a first-in-class, orally active nonsteroidal anti-inflammatory agent (NSAID) which is a dual inhibitor of COX-2 (IC50 around 0.1 μg/ml) and carbonicanhydrase . Polmacoxib inhibits colorectal adenoma and tumor growth in mouse models .
Brinzolamide-d5 (hydrochloride) is the deuterium labeled Brinzolamide hydrochloride[1]. Brinzolamide (AL-4862) hydrochloride is a selective carbonicanhydrase II inhibitor with an IC50 value of 3.2 nM. Brinzolamide hydrochloride reduces intraocular pressure (IOP) by inhibiting ciliary CA-II and decreasing atrial fluid secretion. Brinzolamide hydrochloride can be used in glaucoma disease research[2][3].
Dorzolamide-d5(hydrochloride) (L671152 hydrochloride-d5) is deuterium labeled Dorzolamide (hydrochloride). Dorzolamide (L671152) hydrochloride is a potent carbonicanhydrase II inhibitor, with IC50 values of 0.18 nM and 600 nM for red blood cell CA-II and CA-I respectively. Dorzolamide possesses anti-tumor activity .
CL 5343 (5-Amino-1,3,4-thiadiazole-2-sulfonamide) is an inhibitor of human carbonicanhydrase B (HCA-B). CL 5343 can serve as a CA9 ligand to achieve the targeted delivery of maytansinoid to the cell membrane of SKRC52 renal cancer cells .
CA/MAO-B-IN-1 (Compound 78) is a dual inhibitor for human brain carbonicanhydrases (CA) and Monoamine Oxidase-B (MAO-B), with IC50s of 8.8 and 7.0 nM, respectively. CA/MAO-B-IN-1 reveals a human oral absorption of 71.9% through in silico prediction .
hCA XII/II/IX-IN-1 (Compound 3) is a potent human carbonicanhydrase (hCA)inhibitor with IC50 values of 2.6, 0.004, 0.005 and 0.001 μM against hCA I, hCA II, hCA IX and hCA XII, respectively. hCA XII/II/IX-IN-1 shows anticancer activity .
Zonisamide-d4 is the deuterium labeled Zonisamide. Zonisamide (AD 810) is an inhibitor of zinc enzyme carbonicanhydrase (CA), with Kis of 35.2 nM and 20.6 nM for human mitochondrial isozyme hCA II and hCA V, respectively. Zonisamide has antiepileptic activity. Zonisamide can be used for the rsearch for epilepsy, seizures and Parkinson's disease[1][2].
CAIX/CAXII-IN-4 (Compound 7h) is the inhibitor for carbonicanhydrase (CA) that binds CA IX, CA XII and CA II with Ki of 1.324 μM, 0.435 μM and 3.035 μM. CAIX/CAXII-IN-4 exhibits board-spectrum antitumor efficacy, inhibits the proliferation of CNS cancer U251 with GI50 of 0.361 μM .
CAIX Inhibitor S4 is a potent and selective inhibitor of carbonicanhydrase IX/XII (CA IX/XII), with a Ki of 7 nM and 2 nM, respectively. CAIX Inhibitor S4 also inhibitsCA II and CA I (Ki=546 and 5600 nM, respectively). CAIX Inhibitor S4 can inhibit the number of lung metastasis in orthotopic MDA-MB-231 mouse model without affecting primary tumor growth .
Flurbiprofen sodium (dl-Flurbiprofen sodium) is a nonsteroidal anti-inflammatory agent (NSAID) with anti-inflammatory and analgesic activities. Flurbiprofen sodium is used to reduce bone resorption in periodontal disease, and it works by inhibitingcarbonicanhydrase. Flurbiprofen sodium is formulated as biodegradable microspheres for use as a compound delivery system, particularly within the periodontal pocket. The release rate of flurbiprofen sodium is related to the concentration of polymer and polyvinyl alcohol used in its preparation .
Punicalin is a species that can be isolated from the leaves of Punica granatum. Punicalin is an active molecule against hepatitis b virus (HBV). Punicalin can induce pyroptosis. Punicalin is a Carbonicanhydraseinhibitor. Punicalin blocks the binding of S-glycoprotein and ACE2 receptors. Pnuicalin has anti-inflammatory, antioxidant and antiviral activity .
FC11409B is an ureido-sulfamate carbonicanhydrase IX (CAIX) inhibitor. FC11409B inhibits proliferation and migration of breast cancer cell lines in both hypoxic (0.5% O2) and normoxic conditions (21% O2). FC11409B also inhibits 3D spheroid of breast cancer subtypes invasion. FC11409B is promising for research of breast and ovarian cancers .
hCAIX/XII-IN-5 (Coumarin 9a) a carbonicanhydrase (CA) inhibitor, and exhibits excellent hCA IX/XII selectivity (Ki=93.9 and 85.7 nM, respectively) over hCA I and hCA II. hCAIX/XII-IN-5 shows anti-proliferative activities to cancer cells. hCAIX/XII-IN-5 can delay cell cycle and induce apoptosis .
hCAIX-IN-11 (Compound 5d) is a selective carbonicanhydrase IX and XIIinhibitor with Ki s of 32.7 and 623.5 nM for hCA IX and hCA XII, respectively. hCA IX and hCA XII are transmembrane isoforms which have been characterized as biomarkers for several types of tumors. The hCA XII assists in maintenance of acid-base homoeostasis in normal as well as tumor cells .
Fluorometholone acetate (Standard) is the analytical standard of Fluorometholone acetate. This product is intended for research and analytical applications. Fluorometholone acetate is a synthetic glucocorticoid corticosteroid and a corticosteroid ester. Fluorometholone acetate potently inhibitscarbonicanhydrase (CA) with IC50s of 2.18 μM and 17.5 μM for hCA-I and hCA-II, respectively. Fluorometholone acetate has anti-inflammatory effect and has the potential for external ocular inflammation research .
hCAIX-IN-10 (Compound 6i) is a selective carbonicanhydrase IX and XIIinhibitor with Ki s of 61.5 and 586.8 nM for hCA IX and hCA XII, respectively. hCA IX and hCA XII are transmembrane isoforms which have been characterized as biomarkers for several types of tumors. The hCA XII assists in maintenance of acid-base homoeostasis in normal as well as tumor cells .
hCA/VEGFR-2-IN-1 (compound 13a) is a potent dual CarbonicAnhydrase(CA) IX/XII with Ki values of 4.7 nM and 8.3 nM for hCA XII and hCA IX, respectively. hCA/VEGFR-2-IN-1 (compound 13a) is a potent VEGFR-2inhibitor with IC50 values 26.3 nM. hCA/VEGFR-2-IN-1 has anticancer activity .
DPP IV/hCA II-IN-1 is a potent and selective dipeptidyl peptidase IV (DPP IV) and carbonicanhydrase (CA)inhibitor with an IC50 value of 0.049 μM for DPP IV and with Ki values of 0.0361, 0.0428, 0.0941, 0.1328, 0.2615, and 3.034 μM for CA II, CA VB, CA VA, CA IX, CA I, and CA IV, respectively .
Indisulam (E 7070) is a carbonicanhydraseinhibitor with anticancer activity. Indisulam (E 7070) is a sulfonamide agent that targets the G1 phase of the cell cycle. Indisulam (E 7070) causes a blockade in the G1/S transition through inhibition of the activation of both CDK2 and cyclin E. Indisulam (E 7070) targets splicing by inducing RBM39 degradation via recruitment to DCAF15 .
hCAIX/XII-IN-8 (compound 3g) is a potent human (carbonicanhydrase) CA IX and XIIinhibitor, with Ki values of 8.5 and 6.7 nM, respectively. hCAIX/XII-IN-8 shows particularly strong inhibitory activity against the tumor-associated membrane-bound isoforms, hCA IX and XII, while maintaining a high selectivity ratio over cytosolic off-target isoforms hCA I and II .
WES-1 (Compound 8g) is an inhibitor of carbonicanhydrase IX (Ki: 55.9 μM). WES-1 has broad spectrum anti-proliferative activity against the cancer cells, such as leukemia (K-562 and MOLT-4), non-small cell lung cancer (NCI–H460), colon cancer (HCT 116 and HCT-15) and melanoma (LOX IMVI) cell lines .
Zonisamide (AD 810) sodium is an orally active carbonicanhydraseinhibitor, with Kis of 35.2 and 20.6 nM for hCA II and hCA V, respectively. Zonisamide sodium exerts neuroprotective effects through anti-apoptosis and upregulating MnSOD levels. Zonisamide sodium also increases the expression of Hrd1, thereby improving cardiac function in AAC rats. Zonisamide sodium can be used in studies of seizure, parkinson’s disease and cardiac hypertrophy .
CL 5343 (Standard) is the analytical standard of CL 5343. This product is intended for research and analytical applications. CL 5343 (5-Amino-1,3,4-thiadiazole-2-sulfonamide) is an inhibitor of human carbonicanhydrase B (HCA-B). CL 5343 can serve as a CA9 ligand to achieve the targeted delivery of maytansinoid to the cell membrane of SKRC52 renal cancer cells .
Zonisamide (AD 810) is an orally active carbonicanhydraseinhibitor, with Kis of 35.2 and 20.6 nM for hCA II and hCA V, respectively. Zonisamide exerts neuroprotective effects through anti-apoptosis and upregulating MnSOD levels. Zonisamide also increases the expression of Hrd1, thereby improving cardiac function in AAC rats. Zonisamide can be used in studies of seizure, parkinson’s disease and cardiac hypertrophy .
Antibacterial agent 215 (Compound 3b) is an inhibitor for carbonicanhydrase (CA), with Ki of 17.61, 5.14 and 43.74 nM, for hCA I, hCA II and AChE, respectively. Antibacterial agent 215 exhibits anti-tuberculosis, with MIC of 62.5 µg/ml against M. tuberculosis. Antibacterial agent 215 exhibits antifungal activities against Candida spp. strains ATCC 14053, ATCC 1369, and ATCC 15126, with MICs of 125 µg/ml .
hCAI/II-IN-6 is an orally active human carbonicanhydrase (CA) inhibitor. hCAI/II-IN-6 selectively inhibits hCA II and hCA VII isoforms with Ki values of 220, 4.9, 6.5 and ＞50000 nM for hCA I, hCA II , hCA VII and hCA XII respectively. hCAI/II-IN-6 shows anticonvulsant activity and anti maximal electroshock (MES) activity in vivo. hCAI/II-IN-6 can be used for the research of epilepsy .
hCAIX-IN-23 (Compound 27) is a human carbonicanhydrase (hCA) inhibitor with Ki values of 10.4 and 8.5 nM for hCA IX and hCA XII, respectively. In addition to inhibitinghCA activity, hCAIX-IN-23 releases NO, exhibiting dual antitumor activity. hCAIX-IN-23 induces apoptosis by regulating mitochondrial caspase activity and the ferroptosis pathway (ferroptosis) through the downregulation of hCA IX and iron-regulatory protein expression. hCAIX-IN-23 is useful for renal cancer research .
4-(Chloromethyl)-7-hydroxycoumarin (compound 4) is a hydroxycoumarin derivative with potent antioxidant effect and high hydroxyl radical-scavenging property. 4-(Chloromethyl)-7-hydroxycoumarin contains a methyl group and a chlorine group in the heterocyclic ring. A series of coumarins incorporating hydroxy-, chloro- and/or chloromethyl-moieties has been investigated as potent inhibitors of the zinc enzyme carbonicanhydrase, expecially tumor-associated isoforms CA IX and XII .
Punicalin (Standard) is the analytical standard of Punicalin. This product is intended for research and analytical applications. Punicalin is a species that can be isolated from the leaves of Punica granatum. Punicalin is an active molecule against hepatitis b virus (HBV). Punicalin can induce pyroptosis. Punicalin is a Carbonicanhydraseinhibitor. Punicalin blocks the binding of S-glycoprotein and ACE2 receptors. Pnuicalin has anti-inflammatory, antioxidant and antiviral activity .
Flurbiprofen (sodium) (Standard) is the analytical standard of Flurbiprofen (sodium). This product is intended for research and analytical applications. Flurbiprofen sodium (dl-Flurbiprofen sodium) is a nonsteroidal anti-inflammatory agent (NSAID) with anti-inflammatory and analgesic activities. Flurbiprofen sodium is used to reduce bone resorption in periodontal disease, and it works by inhibitingcarbonicanhydrase. Flurbiprofen sodium is formulated as biodegradable microspheres for use as a compound delivery system, particularly within the periodontal pocket. The release rate of flurbiprofen sodium is related to the concentration of polymer and polyvinyl alcohol used in its preparation .
Flurbiprofen (sodium) (Standard) is the analytical standard of Flurbiprofen (sodium). This product is intended for research and analytical applications. Flurbiprofen sodium (dl-Flurbiprofen sodium) is a nonsteroidal anti-inflammatory agent (NSAID) with anti-inflammatory and analgesic activities. Flurbiprofen sodium is used to reduce bone resorption in periodontal disease, and it works by inhibitingcarbonicanhydrase. Flurbiprofen sodium is formulated as biodegradable microspheres for use as a compound delivery system, particularly within the periodontal pocket. The release rate of flurbiprofen sodium is related to the concentration of polymer and polyvinyl alcohol used in its preparation .
ts-SA is a carbonicanhydrase (CA) inhibitor with activity against seven human CA homologues. ts-SA can bind to the Zn(II) ion in the enzyme active site in a deprotonated form. The organic skeleton of ts-SA extends in the enzyme cavity and participates in multiple interactions with amino acid residues and water molecules. Due to its structural differences, the inhibitory performance of ts-SA is significantly better than that of another pyridine derivative. ts-SA exhibits low nanomolar inhibitory activity and is a multi-target CA inhibitor .
Chlorthalidone Impurity G (Chlorthalidone EP Impurity G) is a potential impurity found in commercial preparations of chlorthalidone with moderate antihypertensive effects. Chlorthalidone is a thiazide diuretic that inhibits the Na+/Cl- cotransporter in the distal tubule of the kidney, thereby preventing sodium and chloride reabsorption, resulting in decreased plasma volume and cardiac output. It also inhibitscarbonicanhydrase (CA), including isoenzymes CAVB, VII, IX, XII, and XIII (Kis=2.8-23 nM) and to a lesser extent CAI, CAII, IV, VA, and VI (Ki=138-1,347 nM), mediating vasodilatory activity.
hCAIX/XII-IN-13 is an inhibitor of human carbonicanhydrases (hCA). hCAIX/XII-IN-13 shows good inhibitory activity against the tumor-related CA subtypes IX and XII, with Ki values of 0.08 µM and 0.06 µM, respectively. Under hypoxic conditions, hCAIX/XII-IN-13 can restore the cytotoxicity of Doxorubicin (HY-15142A) on MCF-7 cells, increasing G2/M phase cell cycle arrest and apoptosis .
hCAI/II-IN-5 (compound MZ8) is a potent hCA I and hCA II (human carbonicanhydrase isoenzymes I and II) inhibitor, with IC50 values of 37.88 and 45.23 nM, respectively. hCAI/II-IN-5 also shows inhibition profile against α-Glycosidase and AChE, with IC50 values of 48.98 and 420.14 nM, respectively. hCAI/II-IN-5 can be used for the research of many diseases such as diabetes, Alzheimer’s disease, heart failure, ulcer, and epilepsy .
Zonisamide (Standard) is the analytical standard of Zonisamide. This product is intended for research and analytical applications. Zonisamide (AD 810) is an orally active carbonicanhydraseinhibitor, with Kis of 35.2 and 20.6 nM for hCA II and hCA V, respectively. Zonisamide exerts neuroprotective effects through anti-apoptosis and upregulating MnSOD levels. Zonisamide also increases the expression of Hrd1, thereby improving cardiac function in AAC rats. Zonisamide can be used in studies of seizure, parkinson’s disease and cardiac hypertrophy .
CA IX/VEGFR-2-IN-3 (Compound 6i) is an inhibitor of CarbonicAnhydrase IX and VEGFR-2, with IC50 values of 41 and 48 nM, respectively. CA IX/VEGFR-2-IN-3 exhibits anticancer activity, inhibiting the growth of MCF-7 breast cancer cells (with an IC50 of 22.33 μM) and mouse fibroblast cell line 3T3 (where cell viability is less than 40% at a concentration of 100 μM). CA IX/VEGFR-2-IN-3 can be used for research in the field of cancer treatment .
α-Glycosidase-IN-1 (compound MZ7) is a potent α-GLY (α-Glycosidase) inhibitor, with an IC50 of 44.72 nM and a KI of 41.74 nM. α-Glycosidase-IN-1 also shows inhibition profile against human carbonicanhydrase isoenzymes I and II (hCA I and hCA II), and acetylcholinesterase (AChE), with IC50 values of 104.87, 100.04, and 654.87 nM, respectively. α-Glycosidase-IN-1 can be used for the research of many diseases such as diabetes, Alzheimer’s disease, heart failure, ulcer, and epilepsy .
Antitumor agent-163 (Compound 3) is a photosensitizer used in Molecular-Targeted Photodynamic Therapy (MT-PDT) targeting carbonicanhydrase IX (CAIX). Antitumor agent-163 inactivates CAIX protein via singlet oxygen under 540 nm wavelength light, without affecting internal standard proteins such as α-tubulin, β-actin, and proliferating cell nuclear antigen (PCNA). Antitumor agent-163 induces cell membrane damage, inhibits cell viability (IC50 is 0.2 and 0.05 μM for A549 and U87MG). Antitumor agent-163 exhibits antitumor efficacy in mouse model .
hA2A/hCA XII modulator 1 (compound 14), a triazolopirazine, is a potent hA2A adenosine receptor (hA2AAR) antagonist with Kis of 6.4 nM, 4.819 μM, >30 μM for hA2AAR, hA1AR, hA3AR, respectively. hA2A/hCA XII modulator 1 is a potent human carbonicanhydrase XII (hCA XII)inhibitor with Kis of 6.2 nM, 46 nM, 466 nM, 8.351 μM for hCA XII, hCA II, hCA IX and hCA I, respectively. hA2A/hCA XII modulator 1 has the potential for cancer research .
CA IX-IN-2 (Compound 9o) is an inhibitor for carbonicanhydrase (CA), that inhibits CA IX, CA XII and CA II with an IC50 of 5.6, 7.4 and 430 nM, respectively. CA IX-IN-2 inhibits the proliferation of cancer cell HCT-116, SW480, MDA-MB 231 and MCF-7, with IC50s of 14.63-29.33 μM. CA IX-IN-2 intercalates DNA, arrests cell cycle at G1/S phase, and induces apoptosis in MDA-MB-231. CA IX-IN-2 affects the mitochondrial membrane potential (MMP), increases the intracellular ROS levels, causes mitochondrial damage, and inhibits the cell migration of MDA-MB-231. CA IX-IN-2 exhibits antitumor efficacy in mouse models .
Punicalin is a species that can be isolated from the leaves of Punica granatum. Punicalin is an active molecule against hepatitis b virus (HBV). Punicalin can induce pyroptosis. Punicalin is a Carbonicanhydraseinhibitor. Punicalin blocks the binding of S-glycoprotein and ACE2 receptors. Pnuicalin has anti-inflammatory, antioxidant and antiviral activity .
Benzenesulphonamide (Standard) is the analytical standard of Benzenesulphonamide. This product is intended for research and analytical applications. Benzenesulphonamide (compound 1) is a potent carbonicanhydraseinhibitor. Benzenesulphonamide shows CA II inhibitory activity .
Lasamide (Standard) is the analytical standard of Lasamide. This product is intended for research and analytical applications. Lasamide is a potent human CarbonicAnhydraseinhibitor with Ki values of 7.54 and 2.76 nM for hCAXII and hCAIX, respectively .
Punicalin (Standard) is the analytical standard of Punicalin. This product is intended for research and analytical applications. Punicalin is a species that can be isolated from the leaves of Punica granatum. Punicalin is an active molecule against hepatitis b virus (HBV). Punicalin can induce pyroptosis. Punicalin is a Carbonicanhydraseinhibitor. Punicalin blocks the binding of S-glycoprotein and ACE2 receptors. Pnuicalin has anti-inflammatory, antioxidant and antiviral activity .
ICA Protein, a potent inhibitor of carbonic anhydrase 2 (CA2), intricately regulates enzymatic activity within a finely tuned network. Functionally, ICA, a non-iron-binding monomer, exhibits specificity in inhibiting CA2. Its transferrin-like domain 2 engages in molecular interactions, underscoring ICA's regulatory role. This positions ICA as a key player, adding nuance to the precise mechanisms governing carbonic anhydrase activity. ICA Protein, Mouse (HEK293, His) is the recombinant mouse-derived ICA protein, expressed by HEK293 , with C-His labeled tag.
Zonisamide-d4 is the deuterium labeled Zonisamide. Zonisamide (AD 810) is an inhibitor of zinc enzyme carbonicanhydrase (CA), with Kis of 35.2 nM and 20.6 nM for human mitochondrial isozyme hCA II and hCA V, respectively. Zonisamide has antiepileptic activity. Zonisamide can be used for the rsearch for epilepsy, seizures and Parkinson's disease[1][2].
Methazolamide-d6 is the deuterium labeled Methazolamide. Methazolamide (L584601) is a sulfonamide derivative used as a carbonicanhydraseinhibitor with a Ki of 14 nM for human carbonicanhydrase II. Methazolamide, an intraocular pressure-lowering agent, reduces intraocular pressure elevations associated with glaucoma and other ocular disorders[1][2].
Acetazolamide- 13C2,d3 is the 13C- and deuterium labeled Acetazolamide. Acetazolamide is a carbonicanhydrase (CA) IX inhibitor with an IC50 of 30 nM for hCA IX[1]. Diuretic effects[4].
Dorzolamide-d5 is the deuterium labeled Dorzolamide. Dorzolamide (L671152) is a potent carbonicanhydrase II inhibitor, with IC50 values of 0.18 nM and 600 nM for red blood cell CA-II and CA-I respectively. Dorzolamide possesses anti-tumor activity[1][2].
Dorzolamide-d3 hydrochloride is deuterated labeled Dorzolamide hydrochloride (HY-B0109A). Dorzolamide (L671152) hydrochloride is a potent carbonicanhydrase II inhibitor, with IC50 values of 0.18 nM and 600 nM for red blood cell CA-II and CA-I respectively. Dorzolamide possesses anti-tumor activity .
Brinzolamide-d5 (hydrochloride) is the deuterium labeled Brinzolamide hydrochloride[1]. Brinzolamide (AL-4862) hydrochloride is a selective carbonicanhydrase II inhibitor with an IC50 value of 3.2 nM. Brinzolamide hydrochloride reduces intraocular pressure (IOP) by inhibiting ciliary CA-II and decreasing atrial fluid secretion. Brinzolamide hydrochloride can be used in glaucoma disease research[2][3].
Dorzolamide-d5(hydrochloride) (L671152 hydrochloride-d5) is deuterium labeled Dorzolamide (hydrochloride). Dorzolamide (L671152) hydrochloride is a potent carbonicanhydrase II inhibitor, with IC50 values of 0.18 nM and 600 nM for red blood cell CA-II and CA-I respectively. Dorzolamide possesses anti-tumor activity .
hCAXII-IN-10 (Compound 18b) is a dual inhibitor of human carbonicanhydrase isoform XII (hCAXII) and cathepsin B, with a Ki value of 2.2 nM. hCAXII-IN-10 can inhibit the role of hCAXII in providing tumors with a pH microenvironment conducive to tumor growth, and is expected to be used in the study of tumor diseases .
Inquiry Online
Your information is safe with us. * Required Fields.
